🍪 The GLP Lounge uses cookies to improve your experience, analyze traffic, and personalize content. By continuing to use this site, you agree to our Cookie Policy.
Evidence-based GLP-1 & peptide discussion since 2023
ForumsPublic SquareNovo Nordisk vs Eli Lilly — the GLP-1 market landscape in 2026 Page 3

Novo Nordisk vs Eli Lilly — the GLP-1 market landscape in 2026

anders_CPH Thu, Mar 19, 2026 at 1:00 PM 22 replies 1,194 viewsPage 3 of 5
Dr.NutriCornell
Senior Member
1,345
6,234
Mar 2024
Ithaca, NY
Mar 22, 2026 at 2:06 AM#11
NurseLeah_Nash said:
Propensity score matching studies and the trial evidence: when RCTs aren't available for a specific question, propensity score-matched observational…

True, and it depends on a baseline nobody has stated. Without knowing where someone started, the same number can be an excellent result or a disappointing one.

Last edited: Mar 22, 2026 at 4:06 AM
4 2emily_PDX, Dr.SleepRoch, laura_annarbor and 1 other
Reply Quote Save Share Report
lisa_labSD
Member
278
1,234
Oct 2024
San Diego, CA
Mar 22, 2026 at 1:45 PM#12
MounjBrad said:
Forest plot interpretation for the the trial evidence meta-analysis: when reading the pooled estimate, pay attention to: Point estimate (HR/RR/OR) —…

This answered a question I did not know how to ask. Taking it to my next appointment.

5 3maya_sedona, stefan_berlin, Dr.EM_Chicago and 2 others
Reply Quote Save Share Report
Dr.PainCLE
Senior Member
1,234
6,234
Mar 2024
Cleveland, OH
Mar 23, 2026 at 1:23 AM#13
NurseLeah_Nash said:
Propensity score matching studies and the trial evidence: when RCTs aren't available for a specific question, propensity score-matched observational…

Pushing back on NurseLeah_Nash here. Pushing back on the consensus forming here. Consistency is not the same as correctness, and a board that agrees with itself quickly is usually agreeing with the first person who sounded certain.

6 4oliver_london, tane_welly, Dr.PathRoch and 3 others
Reply Quote Save Share Report

PeptideMeter — Independent Peptide Analytics

Community-driven peptide testing and vendor rating platform. Transparent results. Unbiased analysis. Trusted by thousands.

View Results
HPLC_Greg
Senior Member
1,890
8,901
Feb 2024
Research Triangle, NC
Mar 23, 2026 at 1:01 PM#14

The figures, for anyone assembling their own picture. Give anything pharmacological four weeks before you judge it, and give anything measured weekly a four-point rolling average before you call it a trend.

7 5Dr.MetabolicMD, RetaRick_CA, JenPlateau and 4 others
Reply Quote Save Share Report
mike_mod
Moderator
7,234
19,823
Nov 2023
New York
Online
Mar 24, 2026 at 12:39 AM#15

Moderator note: a couple of off-topic posts removed. Report rather than reply if it drifts again.

Last edited: Mar 24, 2026 at 2:39 AM
8 6PurityPaulOR, MaxMetOK, MounjBrad and 5 others
Reply Quote Save Share Report

Similar Threads

SELECT trial 4-year follow-up data released — sustained MACE reduction16 replies
GLP-1 receptor agonists and thyroid C-cell concerns — evidence review19 replies
Is there a ceiling effect for GLP-1-mediated weight loss?20 replies
Comparative pharmacokinetics: semaglutide vs tirzepatide vs retatrutide6 replies
My 18-month semaglutide journey — comprehensive data log20 replies
ForumsNewTrendingMembersAccount

Log In

Forgot password?
No account? Register